Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 5/3086% above fair value
$59.90−0.59 (-0.98%)
Close on Oct 30, 2026Market cap $8.46BP/E –Yield –
Earnings
Arrowhead Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 24, 2026
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$75.25M
+171.0% on a year earlier
EPS, Q3 FY2026
-$1.36
-$1.26 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Arrowhead Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Sep 30, 2026 | Nov 24, 2026Expected | – | – | – | – |
| Q3 FY2026ended Jun 30, 2026 | Aug 4, 2026during market hours | $75.25M | +171.0% | -$1.36 | Release |
| Q2 FY2026ended Mar 31, 2026 | May 7, 2026during market hours | $73.74M | – | -$0.93 | Release |
| Q1 FY2026ended Dec 31, 2025 | Feb 5, 2026during market hours | – | – | – | Release |
| Q4 FY2025ended Sep 30, 2025 | Nov 25, 2025during market hours | – | – | – | Release |
| Q3 FY2025ended Jun 30, 2025 | Aug 7, 2025during market hours | $27.77M | – | -$1.26 | Release |
| Q2 FY2025ended Mar 31, 2025 | May 12, 2025during market hours | – | – | – | Release |
| Q1 FY2025ended Dec 31, 2024 | Feb 10, 2025during market hours | $2.50M | -29.6% | -$1.39 | Release |
| Q4 FY2024ended Sep 30, 2024 | Nov 26, 2024during market hours | – | – | – | Release |
| Q3 FY2024ended Jun 30, 2024 | Aug 8, 2024during market hours | – | – | -$1.38 | Release |
| Q2 FY2024ended Mar 31, 2024 | May 9, 2024during market hours | – | – | -$1.02 | Release |
| Q1 FY2024ended Dec 31, 2023 | Feb 6, 2024during market hours | $3.55M | – | -$1.24 | Release |
| Q4 FY2023ended Sep 30, 2023 | Nov 29, 2023during market hours | – | – | – | Release |
| Q3 FY2023ended Jun 30, 2023 | Aug 7, 2023during market hours | $15.83M | -51.2% | -$0.96 | Release |
| Q2 FY2023ended Mar 31, 2023 | May 2, 2023during market hours | $146.27M | -3.6% | $0.45 | Release |
| Q4 FY2022ended Sep 30, 2022 | Nov 28, 2022during market hours | – | – | – | Release |
| Q3 FY2022ended Jun 30, 2022 | Aug 4, 2022during market hours | $32.41M | – | -$0.68 | Release |
| Q2 FY2022ended Mar 31, 2022 | May 10, 2022during market hours | $151.81M | – | $0.41 | Release |
| Q1 FY2022ended Dec 31, 2021 | Feb 2, 2022during market hours | $27.44M | – | -$0.60 | Release |
| Q4 FY2021ended Sep 30, 2021 | Nov 22, 2021during market hours | – | – | – | Release |
| Q3 FY2021ended Jun 30, 2021 | Aug 5, 2021during market hours | – | – | – | Filing |
| Q2 FY2021ended Mar 31, 2021 | May 4, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Dec 31, 2020 | Feb 4, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Sep 30, 2020 | Nov 23, 2020during market hours | – | – | – | Filing |
| Q3 FY2020ended Jun 30, 2020 | Aug 5, 2020during market hours | – | – | – | Filing |
| Q2 FY2020ended Mar 31, 2020 | May 7, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Arrowhead Pharmaceuticals has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Arrowhead Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Arrowhead Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Update
- Update
- Results
- News
- News
- News
- News
- News
- Results
- Results
- Results